Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 14 3 2019
medline: 14 3 2019
entrez: 14 3 2019
Statut: ppublish

Résumé

This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License.

Identifiants

DOI: 10.1038/s41416-019-0433-6 PMID: 30862952 PMC: PMC6474310
pubmed: 30862952
doi: 10.1038/s41416-019-0433-6
pii: 10.1038/s41416-019-0433-6
pmc: PMC6474310
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

868

Commentaires et corrections

Type : ErratumFor

Auteurs

T Goranova (T)

Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK.

D Ennis (D)

Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK.

A M Piskorz (AM)

Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK.

G Macintyre (G)

Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK.

L A Lewsley (LA)

Cancer Research UK Clinical Trials Unit, Glasgow, G12 0YN, UK.

J Stobo (J)

Cancer Research UK Clinical Trials Unit, Glasgow, G12 0YN, UK.

C Wilson (C)

Cancer Research UK Clinical Trials Unit, Glasgow, G12 0YN, UK.

D Kay (D)

Department of Radiology, Gartnavel General Hospital, Glasgow, G12 0YN, UK.

R M Glasspool (RM)

Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, UK.

M Lockley (M)

Barts Cancer Institute, London, EC1M 6BQ, UK.
University College Hospital, London, WC1E 6BD, UK.

E Brockbank (E)

Barts Cancer Institute, London, EC1M 6BQ, UK.

A Montes (A)

Guy's Hospital, London, SE1 9RT, UK.

A Walther (A)

Bristol Haematology and Oncology Centre, Bristol, BS2 8ED, UK.

S Sundar (S)

City Hospital, Birmingham, B18 7QH, UK.

R Edmondson (R)

St Mary's Hospital, Manchester, M13 9WL, UK.

G D Hall (GD)

St James Hospital, Leeds, LS9 7TF, UK.

A Clamp (A)

The Christie Hospital, Manchester, M20 4BX, UK.

C Gourley (C)

Edinburgh Cancer Research Centre, Edinburgh, EH4 2XR, UK.

M Hall (M)

Mount Vernon Cancer Centre, Northwood, HA6 2RN, UK.

C Fotopoulou (C)

Imperial College, London, W12 0HS, UK.

H Gabra (H)

Imperial College, London, W12 0HS, UK.

S Freeman (S)

Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.

L Moore (L)

Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.

M Jimenez-Linan (M)

Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.

J Paul (J)

Cancer Research UK Clinical Trials Unit, Glasgow, G12 0YN, UK.

J D Brenton (JD)

Cancer Research UK Cambridge Institute, Cambridge, CB2 0RE, UK. james.brenton@cruk.cam.ac.uk.
Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. james.brenton@cruk.cam.ac.uk.

I A McNeish (IA)

Institute of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK. iain.mcneish@glasgow.ac.uk.
Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, UK. iain.mcneish@glasgow.ac.uk.

Classifications MeSH